IL161090A0 - Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol - Google Patents

Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol

Info

Publication number
IL161090A0
IL161090A0 IL16109002A IL16109002A IL161090A0 IL 161090 A0 IL161090 A0 IL 161090A0 IL 16109002 A IL16109002 A IL 16109002A IL 16109002 A IL16109002 A IL 16109002A IL 161090 A0 IL161090 A0 IL 161090A0
Authority
IL
Israel
Prior art keywords
taxol
cox
inhibitor
malignancies
treatment
Prior art date
Application number
IL16109002A
Other languages
English (en)
Inventor
Allan Lipton
Lois Mary Witters
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL161090A0 publication Critical patent/IL161090A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16109002A 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol IL161090A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592101P 2001-10-19 2001-10-19
PCT/EP2002/011696 WO2003035081A1 (en) 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol

Publications (1)

Publication Number Publication Date
IL161090A0 true IL161090A0 (en) 2004-08-31

Family

ID=23357099

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16109002A IL161090A0 (en) 2001-10-19 2002-10-18 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol
IL161090A IL161090A (en) 2001-10-19 2004-03-25 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161090A IL161090A (en) 2001-10-19 2004-03-25 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol

Country Status (26)

Country Link
US (1) US7345088B2 (ko)
EP (1) EP1443942B1 (ko)
JP (1) JP2005506371A (ko)
KR (1) KR20040066103A (ko)
CN (1) CN100372539C (ko)
AT (1) ATE382347T1 (ko)
AU (1) AU2002363089B2 (ko)
BR (1) BR0213410A (ko)
CA (1) CA2461085A1 (ko)
CO (1) CO5570672A2 (ko)
DE (1) DE60224429T2 (ko)
DK (1) DK1443942T3 (ko)
EC (1) ECSP045054A (ko)
ES (1) ES2301710T3 (ko)
HK (1) HK1080733A1 (ko)
HU (1) HUP0402061A3 (ko)
IL (2) IL161090A0 (ko)
MX (1) MXPA04003671A (ko)
NO (1) NO20042056L (ko)
NZ (1) NZ532282A (ko)
PL (1) PL367707A1 (ko)
PT (1) PT1443942E (ko)
RU (1) RU2317819C2 (ko)
SI (1) SI1443942T1 (ko)
WO (1) WO2003035081A1 (ko)
ZA (1) ZA200402089B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014766A2 (en) 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187130A (zh) * 1995-06-06 1998-07-08 麦克公司 用二磷酸盐预防与免疫抑制疗法有关的骨损失
CN1398189A (zh) * 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
EP1253921A4 (en) * 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

Also Published As

Publication number Publication date
WO2003035081A1 (en) 2003-05-01
RU2004115337A (ru) 2005-04-20
RU2317819C2 (ru) 2008-02-27
PT1443942E (pt) 2008-04-07
ZA200402089B (en) 2005-06-22
BR0213410A (pt) 2004-11-03
CN100372539C (zh) 2008-03-05
DE60224429D1 (de) 2008-02-14
CO5570672A2 (es) 2005-10-31
NO20042056L (no) 2004-05-18
CA2461085A1 (en) 2003-05-01
ECSP045054A (es) 2004-05-28
EP1443942B1 (en) 2008-01-02
CN1703226A (zh) 2005-11-30
MXPA04003671A (es) 2005-06-20
ES2301710T3 (es) 2008-07-01
US20050014726A1 (en) 2005-01-20
KR20040066103A (ko) 2004-07-23
HK1080733A1 (en) 2006-05-04
DK1443942T3 (da) 2008-05-19
HUP0402061A2 (hu) 2005-02-28
NZ532282A (en) 2006-02-24
US7345088B2 (en) 2008-03-18
IL161090A (en) 2010-04-15
EP1443942A1 (en) 2004-08-11
HUP0402061A3 (en) 2007-05-29
JP2005506371A (ja) 2005-03-03
SI1443942T1 (sl) 2008-08-31
AU2002363089B2 (en) 2006-02-16
DE60224429T2 (de) 2008-12-18
PL367707A1 (en) 2005-03-07
ATE382347T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
MY141584A (en) Pharmaceutical uses of bisphosphonates
DE60129242D1 (de) Verwendung von zoledronsäure zur schmerzbehandlung
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
RS20050344A (en) Treatment for hemorrhagic shock
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
GB0020504D0 (en) Therapeutic method
MXPA05006722A (es) Metodo para tratamiento de pacientes con exposicion a radiacion.
WO2002015894A3 (en) Use of vitamin d derivatives as bone resorption inhibitors
WO2000059485A3 (en) Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
AU5434899A (en) Cancer treatment
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
BR0308105A (pt) Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UA36041A (uk) Спосіб лікування хронічного панкреатиту, ускладненого псевдокістою
ATE411014T1 (de) Bakuchiol enthaltende pharmazeutische zusammensetzung zur behandlung von weiblichem brustkrebs